Myriad Genetics, Inc
Price
FilingsNewest: 8-K, Director or officer changeSep 16 →Insiders3 insiders bought $722,223 in 5 open-market buys. 1 insider sold $66,900 in 1 sale, on a 10b5-1 plan.→HoldersBlackRock 11.4%Millennium 6.9%Vestal Point Capital 6.0%→Financing →PeersClosest companies: NTRA, VCYT, BLLN→
From the filings
Figures
- Revenue
- $806.6Mlast 12 months
- Net income
- −$112.6Mlast 12 months
- Operating cash flow
- $2.4Mlast 12 months
- Cash and equivalents
- $115.2Mat the last balance sheet
- Total debt
- $120.7Mat the last balance sheet
- Shares outstanding
- 95.6M shareson issue